Business Context and Reporting Period
Company: Autolus Therapeutics Plc (AUTL)
Filing Type: Form 10-Q (Voluntary filing by Foreign Private Issuer)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Commercial-stage biopharmaceutical company developing programmed T cell therapies. The company's primary commercial product is AUCATZYL (obecabtagene autoleucel), approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) in the U.S. (Nov 2024) and U.K. (Jan 2026). EU launch is currently on hold.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenue | $45,689 | $20,923 | $71,907 | $29,905 |
| Net Loss | $(39,111) | $(47,917) | $(110,709) | $(118,081) |
| Operating Loss | $(43,838) | $(61,217) | $(103,351) | $(126,457) |
| Cash & Cash Equivalents | $171,414 | $104,132 | $171,414 | $123,825 |
| Marketable Securities | $30,216 | $196,578 | $30,216 | $196,578 |
| Net Cash Used in Operating Activities | $(90,386) | $(148,346) | $(90,386) | $(148,346) |
| Cost of Sales Margin | 45% | 117% | 63% | 142% |
Note: Margins calculated as Cost of Sales / Total Revenue. Negative margins in 2025 reflect early-stage commercialization costs exceeding revenue.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 118% year-over-year (Q2) and 140% (6M), driven by increased AUCATZYL doses in the U.S. and the January 2026 launch in the U.K.
- Cost Efficiency: Cost of sales as a percentage of revenue improved significantly (from 117% to 45% in Q2) due to higher volumes, operational efficiency initiatives, and the utilization of "zero cost" inventory (materials expensed as R&D prior to approval).
- Restructuring: In April 2026, the company announced a workforce reduction of ~13% to improve efficiency. Approximately $4.2 million in severance costs were recognized in the first half of 2026, contributing to higher SG&A expenses.
- Interest Expense: Net interest expense fluctuated due to cumulative catch-up adjustments on liabilities related to future royalties and milestones (Blackstone and BioNTech agreements).
- Investing Activities: Net cash provided by investing activities was $164.1 million (6M 2026), primarily due to $182.4 million in proceeds from maturities of marketable securities.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash ($171.4M), marketable securities ($30.2M), and proceeds from a new $75M credit facility with Perceptive Advisors (closed July 2026) to fund operations for at least 12 months.
- Financing: The Perceptive facility allows for up to $250M in aggregate principal, with additional tranches contingent on revenue milestones. Interest is SOFR + 7.25% (floor 3.50%).
- Commercialization: EU launch remains on hold while pricing and market entry feasibility are evaluated. No EU revenue is anticipated in 2026.
- Risks:
- Uncertainty regarding U.K. R&D tax credit eligibility (R&D intensive scheme vs. SME scheme).
- Dependence on AUCATZYL for revenue; other pipeline candidates (AUTO8, AUTO4-7) are in early clinical stages.
- Significant liabilities related to future royalties and milestones ($284.3M as of June 30, 2026).
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of AUCATZYL sales in the U.S. and U.K. to ensure they can offset the high fixed costs of commercialization.
- Restructuring Impact: Confirm the realization of the projected $15M annualized cost savings from the April 2026 workforce reduction.
- Debt Obligations: Review the terms of the Perceptive Advisors facility and the magnitude of royalty/milestone liabilities to Blackstone and BioNTech.
- Tax Credit Status: Monitor the resolution of the U.K. tax authority discussions regarding the R&D intensive scheme, which impacts cash flow projections.
- EU Strategy: Assess the timeline and feasibility of the paused EU launch, particularly in Germany.